Brii Biosciences Ltd
Brii Biosciences Ltd is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for infectious diseases and immuno-oncology.
Business. Brii Biosciences Ltd (2137.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Brii Biosciences Ltd (2137.HK) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily engaged in pharmaceuticals and medical research activities. It is listed on the Hong Kong Stock Exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Brii Biosciences has a basic and diluted share count of 721.8 million, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, the company's liquidity risk remains unassessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which limits the ability to evaluate its short-term financial stability.
Profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics are provided for comparison. This lack of data prevents a direct assessment of Brii Biosciences' returns or margins relative to its industry peers.
The company's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the risk associated with its business segments or regional dependencies.
Growth trajectory is not quantified in the current outlook, as no numeric deltas or revenue history are provided. Analysts have issued a single "Hold" recommendation with no "Buy" or "Strong Buy" ratings, suggesting a neutral stance on the stock.
The risk assessment indicates a low dilution potential, but the absence of liquidity data and the lack of going-concern language in source documents raise concerns about the company's ability to meet short-term obligations. No adjustments have been applied to the valuation metrics, and no custom valuations are available for further analysis.
Recent events, including filings and transcripts, are not detailed in the available data, limiting the ability to assess any material developments that may impact the company's operations or financial position.
- Brii Biosciences has no immediate dilution pressure based on current share counts.
- Analysts have issued a single "Hold" recommendation, with no "Buy" or "Strong Buy" ratings.
- The company's liquidity risk remains unassessed due to missing balance-sheet data.
- No profitability metrics or industry comparisons are available for evaluation.
- Revenue concentration and geographic exposure are not disclosed in the available data.
- No recent events or material developments are detailed in the source documents.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥18.6M; Operating income +56,8% YoY.
- ▍Revenue ¥18.6M
- ▍Operating income +56,8% YoY
- ▍Net income +56,2% YoY
- ▍Free cash flow +31,9% YoY
- ▍Net margin -1196.6%
Revenue ¥617.0k, −98,8% YoY; Operating income +62,4% YoY.
- ▍Revenue ¥617.0k, −98,8% YoY
- ▍Operating income +62,4% YoY
- ▍Net income +63,9% YoY
- ▍Free cash flow +64,3% YoY
- ▍Net margin -28335.3%
Revenue ¥51.6M; Operating income +88,3% YoY.
- ▍Revenue ¥51.6M
- ▍Operating income +88,3% YoY
- ▍Net income +88,4% YoY
- ▍Free cash flow +85,3% YoY
- ▍Net margin -938.1%
Revenue ¥0.00; Operating income -¥4.19B.
- ▍Revenue ¥0.00
- ▍Operating income -¥4.19B
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,45 |
| Revenue | —no estimate | —no estimate | 0 CNY |
| Operating income | —no estimate | —no estimate | -394,5M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Brii Biosciences Ltd Market data — financials · 2026-05-26
- Brii Biosciences Ltd Market data — analyst estimates · 2026-05-26